Virtu Financial LLC Humanigen, Inc Transaction History

Virtu Financial LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 15, 2023	BUY	$0.09 - $0.2 $18,827 - $41,839	209,195 Added 225.92%	301,792 $36,000
Q3 2022 Nov 07, 2022	BUY	$0.15 - $3.02 $13,889 - $279,642	92,597 New	92,597 $17,000
Q2 2022 Aug 09, 2022	SELL	$1.76 - $3.33 $65,934 - $124,751	-37,463 Closed	0 $0
Q1 2022 May 17, 2022	BUY	$1.81 - $3.97 $28,214 - $61,884	15,588 Added 71.26%	37,463 $113,000
Q4 2021 Feb 17, 2022	BUY	$3.66 - $8.22 $80,062 - $179,812	21,875 New	21,875 $81,000
Q3 2021 Nov 12, 2021	SELL	$5.93 - $17.83 $217,654 - $654,432	-36,704 Closed	0 $0
Q2 2021 Sep 17, 2021	BUY	$13.54 - $22.74 $159,677 - $268,172	11,793 Added 47.34%	36,704 $638,000
Q1 2021 May 19, 2021	BUY	$12.91 - $23.83 $100,594 - $185,683	7,792 Added 45.52%	24,911 $476,000
Q4 2020 Feb 24, 2021	BUY	$7.97 - $21.66 $136,438 - $370,797	17,119 New	17,119 $300,000

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Virtu Financial LLC with notifications on news.